Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 161 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Topiramate Clear all
Completed Phase 1 Interventional

Preventing Brain Injury in Infants With Congenital Heart Disease

NCT01426542
View directory record Official record
Conditions
Cyanotic Congenital Heart Disease
Interventions
Topiramate, No medication, but routine heart surgery
Drug · Other
Lead sponsor
University of California, Davis
Other
Eligibility
Up to 2 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 17, 2026, 12:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate

NCT01950520
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Propranolol, Pindolol, Dantrolene, Magnesium Sulfate, Caffeine, Qsymia, Topiramate, Phentermine, Naltrexone, Mirabegron 50mg, Mirabegron 200mg, Placebo Cohort 1, Placebo Cohort 2, Placebo for Mirabegron
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 35 Years · Male only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 17, 2026, 12:29 AM EDT
Not listed Phase 2 Interventional

A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis

NCT00217295
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Avonex and Topamax
Drug
Lead sponsor
Multiple Sclerosis Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 22, 2005 · Synced Oct 17, 2026, 12:29 AM EDT
Completed Early Phase 1 Interventional Results available

Efficacy and Safety of Topiramate in the Treatment of Sleep-Related Eating Disorder

NCT00606411
View directory record Official record
Conditions
Sleep-Related Eating Disorder
Interventions
Topiramate or Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 17, 2026, 12:29 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Safety of Intravenous Topiramate in Adult Patients

NCT00753493
View directory record Official record
Conditions
Epilepsy, Migraines
Interventions
intravenous topiramate
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 17, 2026, 12:29 AM EDT
Completed Phase 4 Interventional

Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder

NCT00211744
View directory record Official record
Conditions
Obsessive-compulsive Disorder
Interventions
topiramate
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 17, 2026, 12:29 AM EDT
Completed Phase 2 Interventional Results available

A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence

NCT00421603
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Adderall-XR and Topiramate, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 17, 2026, 12:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.

NCT00842400
View directory record Official record
Conditions
Obesity
Interventions
Metformin, VI-0521, Sitagliptan, Probenecid
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 21, 2010 · Synced Oct 17, 2026, 12:29 AM EDT
Terminated Phase 2 Interventional Results available

Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease

NCT01789047
View directory record Official record
Conditions
Idiopathic Parkinson's Disease, Drug Induced Dyskinesia
Interventions
Topiramate, Placebo, Amantadine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
30 Years to 90 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 17, 2026, 12:29 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults

NCT00563368
View directory record Official record
Conditions
Obesity
Interventions
VI-0521, topiramate, phentermine
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 17, 2026, 12:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Topiramate Alone and in Combination With the Nicotine Patch for Smoking Cessation: A Pilot Study

NCT00755716
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Placebo (sugar pill), Topiramate, Nicotine patch
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Oct 17, 2026, 12:29 AM EDT
Recruiting Not applicable Interventional

Combining a Smartphone App With Medications to Manage Heavy Drinking

NCT06303778
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
Stand Down mobile app, Standard Care
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
15
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 17, 2026, 12:29 AM EDT
Completed Phase 3 Interventional

Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder

NCT00187928
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Topiramate
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 5, 2011 · Synced Oct 17, 2026, 12:29 AM EDT
Terminated Phase 2 Interventional Results available

Topiramate's Effects on Heavy Drinking

NCT02074904
View directory record Official record
Conditions
Alcohol Drinking
Interventions
Topiramate, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 17, 2026, 12:29 AM EDT
Completed Phase 2 Interventional Results available

Topiramate for Alcohol and Cocaine Dependence

NCT00167245
View directory record Official record
Conditions
Alcoholism, Cocaine Dependence
Interventions
Topiramate, placebo
Drug
Lead sponsor
Kyle Kampman
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 17, 2026, 12:29 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures

NCT01142193
View directory record Official record
Conditions
Epilepsy
Interventions
USL255, Placebo
Drug
Lead sponsor
Upsher-Smith Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
19
States / cities
Phoenix, Arizona • Ventura, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 17, 2026, 12:29 AM EDT
Completed Phase 2 Interventional Results available

Topiramate for the Treatment of Methamphetamine Dependence - 1

NCT00345371
View directory record Official record
Conditions
Methamphetamine
Interventions
Topiramate, Placebo Oral Tablet
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 99 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
8
States / cities
Costa Mesa, California • San Diego, California • Torrance, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 17, 2026, 12:29 AM EDT
Withdrawn Phase 4 Interventional

Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department

NCT02945839
View directory record Official record
Conditions
Migraine
Interventions
Preventative Medication (PM), Enhanced Usual Care, PMR (progressive muscle relaxation therapy)
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 17, 2026, 12:29 AM EDT
Completed Phase 4 Interventional Results available

Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine

NCT00394095
View directory record Official record
Conditions
Bipolar Disorder, Weight Gain
Interventions
Topiramate, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
10 Years to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 17, 2026, 12:29 AM EDT
Withdrawn Phase 3 Interventional

The Use of Anticonvulsants for Treatment of Patients With Alcohol Dependence and Post Traumatic Stress Disorder

NCT00571246
View directory record Official record
Conditions
Alcohol Dependence, Post Traumatic Stress Disorder
Interventions
Topiramate, lamotrigine, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 17, 2026, 12:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients

NCT01834404
View directory record Official record
Conditions
Obesity
Interventions
Phentermine-Topiramate ER, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 17, 2026, 12:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Topiramate-Phentermine Combinations for Cocaine Dependence

NCT02239913
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Cocaine, Placebo, Phentermine, Topiramate
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 17, 2026, 12:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of VI-0521 Subjects With Renal Impairment

NCT00768404
View directory record Official record
Conditions
Renal Impairment
Interventions
Topirmate and Phentermine
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Anaheim, California • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Oct 17, 2026, 12:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults

NCT00518466
View directory record Official record
Conditions
Obesity
Interventions
topiramate, phentermine
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 17, 2026, 12:29 AM EDT